Skip to main content
Top
Published in: Journal of Gastroenterology 7/2018

01-07-2018 | Original Article—Liver, Pancreas, and Biliary Tract

A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort

Authors: Yutaka Suzuki, Toshiyuki Mori, Masaaki Yokoyama, Sangchul Kim, Hirokazu Momose, Ryota Matsuki, Masaharu Kogure, Nobutsugu Abe, Hiroyuki Isayama, Takahiro Nakazawa, Kenji Notohara, Atsushi Tanaka, Toshio Tsuyuguchi, Susumu Tazuma, Hajime Takikawa, Masanori Sugiyama

Published in: Journal of Gastroenterology | Issue 7/2018

Login to get access

Abstract

Background

Hepatolithiasis frequently results in severe complications. We conducted a cohort study to identify prognostic factors and to establish a hepatolithiasis severity classification system.

Methods

The study cohort comprised 396 patients who were identified through a 1998 nationwide survey and followed up for 18 years or until death. Cox regression analysis was used to identify prognostic factors.

Results

Median survival time of the patients was 308 (range 0–462) months. Of the 396 patients enrolled in the study, 118 (29.8%) died, most frequently from intrahepatic cholangiocarcinoma (25 patients, 21.2%). Age of ≥ 65 years at the time of initial diagnosis [hazard ratio (HR) 3.410], jaundice for ≥ 1 week during follow-up (HR 2.442), intrahepatic cholangiocarcinoma (HR 3.674), and liver cirrhosis (HR 5.061) were shown to be significant risk factors for death from any therapeutic course. The data led to a 3-grade disease severity classification system that incorporates intrahepatic cholangiocarcinoma and liver cirrhosis as major factors and age of ≥ 65 years and jaundice for ≥ 1 week during follow-up as minor factors. Survival rates differed significantly between grades.

Conclusions

The proposed hepatolithiasis severity classification system can be used to assess prognosis and thereby improve patient outcomes.
Literature
1.
go back to reference Tazuma S, Unno M, Igarashi Y, et al. Evidence-based clinical practice guidelines for cholelithiasis 2016. J Gastroenterol. 2017;52:276–300.CrossRefPubMed Tazuma S, Unno M, Igarashi Y, et al. Evidence-based clinical practice guidelines for cholelithiasis 2016. J Gastroenterol. 2017;52:276–300.CrossRefPubMed
2.
go back to reference Suzuki Y, Mori T, Abe N, et al. Predictive factors for cholangiocarcinoma associated with hepatolithiasis determined since Japanese multicenter study. Hepatol Res. 2012;42:166–70.CrossRefPubMed Suzuki Y, Mori T, Abe N, et al. Predictive factors for cholangiocarcinoma associated with hepatolithiasis determined since Japanese multicenter study. Hepatol Res. 2012;42:166–70.CrossRefPubMed
3.
go back to reference Suzuki Y, Mori T, Yokoyama M, et al. Hepatolithiasis: analysis of Japanese nationwide surveys over a period of 40 years. J Hepatobiliary Pancreat Sci. 2014;21:617–22.CrossRefPubMed Suzuki Y, Mori T, Yokoyama M, et al. Hepatolithiasis: analysis of Japanese nationwide surveys over a period of 40 years. J Hepatobiliary Pancreat Sci. 2014;21:617–22.CrossRefPubMed
4.
go back to reference Ohta T, Nagakawa T, Ueda N, et al. Mucosal dysplasia of the liver and the intraductal variant of peripheral cholangiocarcinoma in hepatolithiasis. Cancer. 1991;68:2217–23.CrossRefPubMed Ohta T, Nagakawa T, Ueda N, et al. Mucosal dysplasia of the liver and the intraductal variant of peripheral cholangiocarcinoma in hepatolithiasis. Cancer. 1991;68:2217–23.CrossRefPubMed
5.
go back to reference Chijiiwa K, Ichimiya H, Kuroki S, et al. Late development of cholangiocarcinoma after the treatment of hepatolithiasis. Surg Gynecol Obstet. 1993;177:279–82.PubMed Chijiiwa K, Ichimiya H, Kuroki S, et al. Late development of cholangiocarcinoma after the treatment of hepatolithiasis. Surg Gynecol Obstet. 1993;177:279–82.PubMed
6.
go back to reference Chijiiwa K, Yamashita H, Yoshida J, et al. Current management and long-term prognosis of hepatolithiasis. Arch Surg. 1995;130:194–7.CrossRefPubMed Chijiiwa K, Yamashita H, Yoshida J, et al. Current management and long-term prognosis of hepatolithiasis. Arch Surg. 1995;130:194–7.CrossRefPubMed
7.
go back to reference Kubo S, Kinoshita H, Hirohashi K, et al. Hepatolithiasis associated with cholangiocarcinoma. World J Surg. 1995;19:637–41.CrossRefPubMed Kubo S, Kinoshita H, Hirohashi K, et al. Hepatolithiasis associated with cholangiocarcinoma. World J Surg. 1995;19:637–41.CrossRefPubMed
8.
go back to reference Chijiiwa K, Ohtani K, Noshiro H, et al. Cholangiocellular carcinoma depending on the kind of intrahepatic calculi in patients with hepatolithiasis. Hepatogastroenterology. 2002;49:96–9.PubMed Chijiiwa K, Ohtani K, Noshiro H, et al. Cholangiocellular carcinoma depending on the kind of intrahepatic calculi in patients with hepatolithiasis. Hepatogastroenterology. 2002;49:96–9.PubMed
9.
10.
go back to reference Tabrizian P, Jibara G, Shrager B, et al. Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg. 2012;215:622–6.CrossRefPubMed Tabrizian P, Jibara G, Shrager B, et al. Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg. 2012;215:622–6.CrossRefPubMed
11.
go back to reference Kim HJ, Kim JS, Suh SJ, et al. Cholangiocarcinoma risk as long-term outcome after hepatic resection in the hepatolithiasis patients. World J Surg. 2015;39:1537–42.CrossRefPubMed Kim HJ, Kim JS, Suh SJ, et al. Cholangiocarcinoma risk as long-term outcome after hepatic resection in the hepatolithiasis patients. World J Surg. 2015;39:1537–42.CrossRefPubMed
12.
go back to reference Isa T, Kusano T, Shimoji H, et al. Predictive factors for long-term survival in patients intrahepatic cholangiocarcinoma. Am J Surg. 2001;181:507–11.CrossRefPubMed Isa T, Kusano T, Shimoji H, et al. Predictive factors for long-term survival in patients intrahepatic cholangiocarcinoma. Am J Surg. 2001;181:507–11.CrossRefPubMed
13.
go back to reference Jeng KS, Shih SC, Chiang HJ, et al. Secondary biliary cirrhosis. A limiting factors in the treatment of hepatolithiasis. Arch Surg. 1989;124:1301–5.CrossRefPubMed Jeng KS, Shih SC, Chiang HJ, et al. Secondary biliary cirrhosis. A limiting factors in the treatment of hepatolithiasis. Arch Surg. 1989;124:1301–5.CrossRefPubMed
14.
go back to reference Pu Q, Zhang C, Zhang C, et al. Choledochoscopic lithotripsy is a useful adjunct to laparoscopic common bile duct exploration for hepatolithiasis: a cohort study. Am J Surg. 2016;211:1058–63.CrossRefPubMed Pu Q, Zhang C, Zhang C, et al. Choledochoscopic lithotripsy is a useful adjunct to laparoscopic common bile duct exploration for hepatolithiasis: a cohort study. Am J Surg. 2016;211:1058–63.CrossRefPubMed
15.
16.
go back to reference Kurumaya H, Terada T, Nakanuma Y. ‘Metaplastic lesions’ in intrahepatic bile ducts in hepatolithiasis: a histochemical and immunohistochemical study. J Gastroenterol Hepatol. 1990;5:530–6.CrossRefPubMed Kurumaya H, Terada T, Nakanuma Y. ‘Metaplastic lesions’ in intrahepatic bile ducts in hepatolithiasis: a histochemical and immunohistochemical study. J Gastroenterol Hepatol. 1990;5:530–6.CrossRefPubMed
17.
go back to reference Sato Y, Sasaki M, Harada K, et al. Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraductal neoplasia. J Gastroenterol. 2014;49:64–72.CrossRefPubMed Sato Y, Sasaki M, Harada K, et al. Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraductal neoplasia. J Gastroenterol. 2014;49:64–72.CrossRefPubMed
Metadata
Title
A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort
Authors
Yutaka Suzuki
Toshiyuki Mori
Masaaki Yokoyama
Sangchul Kim
Hirokazu Momose
Ryota Matsuki
Masaharu Kogure
Nobutsugu Abe
Hiroyuki Isayama
Takahiro Nakazawa
Kenji Notohara
Atsushi Tanaka
Toshio Tsuyuguchi
Susumu Tazuma
Hajime Takikawa
Masanori Sugiyama
Publication date
01-07-2018
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 7/2018
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-017-1410-6

Other articles of this Issue 7/2018

Journal of Gastroenterology 7/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.